News
06-29-2015, 10:01 PM
PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.
More... (http://www.news-medical.net/news/20150630/PharmaMar-begins-PM1183-phase-III-study-in-patients-with-platinum-resistant-ovarian-cancer.aspx)
More... (http://www.news-medical.net/news/20150630/PharmaMar-begins-PM1183-phase-III-study-in-patients-with-platinum-resistant-ovarian-cancer.aspx)